Tanimilast - Chiesi Farmaceutici
Alternative Names: CHF 6001 NEXThaler DPI; CHF 6001 NEXThaler®; CHF-6001; CHF6001 DPILatest Information Update: 03 Apr 2025
At a glance
- Originator Chiesi Farmaceutici
- Class Antiallergics; Antiasthmatics; Benzoates; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Phenyl ethers; Pyridines; Small molecules; Sulfonamides
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic obstructive pulmonary disease
- Phase II Allergic asthma; Asthma
Most Recent Events
- 31 Mar 2025 Chiesi Farmaceutici plans a phase II trial in Asthma (In adolescents, In adults, In the elderly) in Bulgaria (Inhalation) (NCT06900816) (EUCT2024-516483-29-00 )
- 18 Mar 2025 Phase-I clinical trials in Chronic obstructive pulmonary disease (In volunteers) in Bulgaria (Inhalation) (NCT06892756)(EudraCT2024-516475-32-00)
- 18 Mar 2025 Chiesi Farmaceutici plans a phase I pharmacokinetics trial (In volunteers) (Inhalation, Powder) in March 2025 (NCT06892756)